Uploaded July 2018 | Updated September 2026, 2 hours ago
Aubrey de Grey (@aubreydegrey) is Cambridge researcher and Chief Science Officer of SENS Research Foundation focused on aging and extending human longevity. He proposes that the first human beings who will live to 1,000 years old have already been born.
In addition to his research, Aubrey is editor-in-chief of the academic journal Rejuvenation Research, author of The Mitochondrial Free Radical Theory of Aging (1999) and co-author of Ending Aging (2007). De Grey’s research focuses on whether regenerative medicine can prevent the aging process. He works on the development of what he calls “Strategies for Engineered Negligible Senescence” (SENS), a collection of proposed techniques to rejuvenate the human body and stop aging. To this end, he has identified seven types of molecular and cellular damage caused by essential metabolic processes. SENS is a proposed panel of therapies designed to repair this damage.
He has been interviewed by most major news sources, including CBS 60 Minutes, the BBC, The New York Times, Fortune Magazine, The Washington Post, TED, Popular Science, The Colbert Report, Time and the Skeptics’ Guide to the Universe.
In our wide-ranging conversation, we cover many things, including:
Why Aubrey switched from studying AI to the science of human longevity
The causes of aging and how we can “cure” them
Why prevention is orders of magnitude more effective than intervention
The reason Aubrey believes some humans today will live to be 1000 years old
Why there isn’t enough funding or support currently for fighting aging
The reason stem cell research is progressing rapidly and proving fruitful
How caloric restriction effects metabolism and aging
Why SENS often spins out businesses to further their aims
The science of immortality
How mainstream media has reacted to prospect of increasing lifespan
*** http://fringe.fm ***
Prefer podcasts? Subscribe today to get episodes delivered free to your phone:
iTunes: *** http://fringe.fm/itunes ***
Android: *** http://fringe.fm/android ***
Aubrey de Grey (@aubreydegrey) is Cambridge researcher and Chief Science Officer of SENS Research Foundation focused on aging and extending human longevity. He proposes that the first human beings who will live to 1,000 years old have already been born.
In addition to his research, Aubrey is editor-in-chief of the academic journal Rejuvenation Research, author of The Mitochondrial Free Radical Theory of Aging (1999) and co-author of Ending Aging (2007). De Grey’s research focuses on whether regenerative medicine can prevent the aging process. He works on the development of what he calls “Strategies for Engineered Negligible Senescence” (SENS), a collection of proposed techniques to rejuvenate the human body and stop aging. To this end, he has identified seven types of molecular and cellular damage caused by essential metabolic processes. SENS is a proposed panel of therapies designed to repair this damage.
He has been interviewed by most major news sources, including CBS 60 Minutes, the BBC, The New York Times, Fortune Magazine, The Washington Post, TED, Popular Science, The Colbert Report, Time and the Skeptics’ Guide to the Universe.
In our wide-ranging conversation, we cover many things, including:
Why Aubrey switched from studying AI to the science of human longevity
The causes of aging and how we can “cure” them
Why prevention is orders of magnitude more effective than intervention
The reason Aubrey believes some humans today will live to be 1000 years old
Why there isn’t enough funding or support currently for fighting aging
The reason stem cell research is progressing rapidly and proving fruitful
How caloric restriction effects metabolism and aging
Why SENS often spins out businesses to further their aims
The science of immortality
How mainstream media has reacted to prospect of increasing lifespan
*** http://fringe.fm ***
Prefer podcasts? Subscribe today to get episodes delivered free to your phone:
iTunes: *** http://fringe.fm/itunes ***
Android: *** http://fringe.fm/android ***
